Investor Relations

Consolidated Earnings Briefing

Kaken Pharmaceutical Co., Ltd. and Consolidated Subsidiaries

2016 2015
For the years ended March 31, Millions of yen
Net sales ¥109,730 ¥93,889
Operating income 35,146 20,631
Net income 21,143 12,122
At March 31,
Total net assets 89,875 77,100
Total assets 132,991 115,135
Per share data: Yen
Net income (Basic) ¥510.54 ¥290.90
* The Company conducted a reverse stock split to consolidate every two shares of common stock into one share on October 1, 2015. Basic earnings per share has been calculated assuming that the reverse stock split was conducted at the beginning of the previous consolidated fiscal year.
Cash dividends
End of second quarter 34.00 27.00
Year-end 78.00 32.00
Total - 59.00
* The Company conducted a reverse stock split to consolidate every two shares of common stock into one share on October 1, 2015. The amount from before the reverse stock split is listed in the end of the second quarter, the year-end cash dividends per share for fiscal 2015 is the amount that factors in this reverse stock split, and total annual cash dividends are described as “-.”
ROE (%) 25.3 16.7
Capital adequacy ratio (%) 67.6 67.0

Forecasts

May 12, 2016

Forecasts of consolidated business results for the fiscal year ending March 2017
(April 1, 2016 - March 31, 2017 )

Full year
Millions of yen
Sales ¥106,100
Operating income 28,900
Net income 20,800

The above forecasts are based on the information available as of the date of the announcement of this data and assumptions made on the same day regarding various uncertainties that may affect our business results in the future. Actual business results may be greatly affected by various factors.